Di Xie

4.5k citations
84 papers · 2.8k indexed · 1 hit paper · h-index 28
Topics
Chronic Kidney Disease and Diabetes (19 papers)Renal Diseases and Glomerulopathies (9 papers)Advanced Glycation End Products research (7 papers)
Partner nations
ChinaUnited StatesJapan

In The Last Decade

Di Xie

80 papers receiving 2.7k citations

Hit Papers

Efficacy and Safety of Benazepril for Advanced Chronic Re...20062026201220192006100200300400500

Peers

Di Xie
Comparison fields: 5 of 119
  • Nephrology 952
  • Cardiology and Cardiovascular Medicine 670
  • Molecular Biology 555
  • Endocrinology, Diabetes and Metabolism 434
  • Clinical Biochemistry 350
Replace Niansong Wang with:
Niansong Wang China
Yoon Sik Chang South Korea
Cheol Whee Park South Korea
Bum Soon Choi South Korea
Anil Bhanudas Gaikwad India
Songming Huang China
Zhanjun Jia China
Shu Wakino Japan
Martha Franco Mexico
Mehdi Nematbakhsh Iran
Di Xie relative to Niansong Wang China Niansong Wang's profile →
Citations per field
00.5×1.5×1.8×
Niansong Wang · 1×
Citations per year

Countries citing papers authored by Di Xie

Since Specialization
Citations

This map shows the geographic impact of Di Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Di Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Di Xie more than expected).

Fields of papers citing papers by Di Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Di Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Di Xie. The network helps show where Di Xie may publish in the future.

Co-authorship network of co-authors of Di Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Di Xie. A scholar is included among the top collaborators of Di Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Di Xie. Di Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 5
4 3
5 62
6 8
7 31
8 3
9 4
10 10
11 41
12 16
13 11
14 14
15 7
16 10
17 35
18 37
19 1
20 37

About Di Xie

Di Xie is a scholar working on Nephrology, Clinical Biochemistry and Neurology, having authored 84 papers that have together received 2.8k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (19 papers), Renal Diseases and Glomerulopathies (9 papers) and Advanced Glycation End Products research (7 papers). The work is most often cited by research in Nephrology (952 citations), Clinical Biochemistry (350 citations) and Cardiology and Cardiovascular Medicine (670 citations). Di Xie has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Fan Fan Hou, Guo Bao Wang, Jian Jiang, Min Liang, Zhi Guo, Xun Zhang, Guo Hua Zhang, Xun Zhang, Xun Zhang and Zhan Zhou. Their work appears in journals such as New England Journal of Medicine, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026